Mutations in RAS genes are common in human tumours, but RAS has proved impossible to target with drugs. Its associated NF-κB signalling pathway, however, may turn out to be this tumour gene's Achilles heel.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Towards pathway‐centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway
Clinical and Translational Medicine Open Access 28 July 2015
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Barbie, D. A. et al. Nature 462, 108–112 (2009).
Meylan, E. et al. Nature 462, 104–107 (2009).
Luo, J. et al. Cell 137, 835–848 (2009).
Scholl, C. et al. Cell 137, 821–834 (2009).
Hacker, H. & Karin, M. Sci. STKE 2006, re13 (2006).
Baud, V. & Karin, M. Nature Rev. Drug Discov. 8, 33–40 (2009).
Mayo, M. W. et al. Science 278, 1812–1815 (1997).
Chien, Y. et al. Cell 127, 157–170 (2006).
Engelman, J. A. et al. Nature Med. 14, 1351–1356 (2008).
Dajee, M. et al. Nature 421, 639–643 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Downward, J. A tumour gene's fatal flaws. Nature 462, 44–45 (2009). https://doi.org/10.1038/462044a
Published:
Issue Date:
DOI: https://doi.org/10.1038/462044a
This article is cited by
-
Comparative transcriptomic analysis of circulating endothelial cells in sickle cell stroke
Annals of Hematology (2024)
-
Towards pathway‐centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway
Clinical and Translational Medicine (2015)
-
Narrowing down the real targets
Nature Chemical Biology (2010)
-
The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-κB signaling pathways
Oncogene (2010)
-
Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation
Cancer and Metastasis Reviews (2010)